2025. Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s646. DOI:https://doi.org/10.25251/ta5v8k92.